Alvotech Usa Patent-Cliff Exposure & CMS Drug Spending Portfolio

Alvotech Usa (US): 2 reconciled FDA prescription therapies, $2.0M 2024 CMS Part D & Medicaid spend, and $4,176 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies2
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$2.0M
2024 Medicare Part D Spend$529K
2024 Medicaid Spend$1.5M
California HCAI SB 17 FilingsSpecialty launch notice ($4,176 intro WAC)